Arcutis Biotherapeutics, Inc. (ARQT)
| Previous close | 8.60 |
| Open | 8.79 |
| Bid | 8.53 x 800 |
| Ask | 8.62 x 800 |
| Day's range | 8.57 - 9.07 |
| 52-week range | 1.76 - 15.12 |
| Volume | |
| Avg. volume | 3,870,711 |
| Market cap | 991.204M |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.78 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
GlobeNewswireArcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the cal
Simply Wall St.Industry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts
Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shareholders will have a reason to smile today, with the analysts making...
ZacksIs AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
